B. Riley lowered the firm’s price target on MacroGenics (MGNX) to $3 from $5 and keeps a Neutral rating on the shares. The company’s key operational updates on a more focused oncology pipeline were noted on its earnings call, with management reaffirming guidance for disclosure of two key trial readouts in 2025, the analyst tells investors in a research note. B. Riley believes the end of selling pressure in the follow-up to the string of vobra duo-related disappointments may be nearing.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MGNX:
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue